<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>About Thompson Dean (Avista) by Thompson Dean (Avista)</title>
      <link>https://padlet.com/ThompsonDeanAvista/About</link>
      <description>Founder, co-managing partner, and CEO of Avista Capital Partners, Thompson Dean is a financial services professional with extensive experience investing in middle-market firms in the healthcare, industrial, and communications industries. Under his leadership, Avista Capital Partners and Avista Capital Holdings have pursued a mixed strategy of control buyouts and growth investments and, drawing on experience in investments, management, and operations. Having led the firm for 12 years, Thompson Dean was instrumental in guiding the firm to reach $6 billion of assets under management. 

Prior to his current positions, Mr. Dean worked as managing partner of DLJMB I, II, III, a position he held for a decade. He also served in the same role with DLJ Growth Capital Partners. Previously, he held positions at Goldman Sachs, where he was a vice president in the special finance group. 

Mr. Dean holds a BA in economics and foreign affairs from the University of Virginia and an MBA from Harvard Business School.</description>
      <language>en-us</language>
      <pubDate>2017-02-22 10:35:47 UTC</pubDate>
      <lastBuildDate>2025-12-04 17:02:22 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Youtube</title>
         <author>ThompsonDeanAvista</author>
         <link>https://padlet.com/ThompsonDeanAvista/About/wish/155401667</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://www.youtube.com/watch?v=YTEVky8kjiE" />
         <pubDate>2017-02-22 10:36:43 UTC</pubDate>
         <guid>https://padlet.com/ThompsonDeanAvista/About/wish/155401667</guid>
      </item>
      <item>
         <title></title>
         <author>ThompsonDeanAvista</author>
         <link>https://padlet.com/ThompsonDeanAvista/About/wish/160382428</link>
         <description><![CDATA[]]></description>
         <enclosure url="http://fortune.com/2015/12/02/avista-capital-makes-major-change-to-fund-strategy/" />
         <pubDate>2017-03-15 21:24:31 UTC</pubDate>
         <guid>https://padlet.com/ThompsonDeanAvista/About/wish/160382428</guid>
      </item>
      <item>
         <title></title>
         <author>ThompsonDeanAvista</author>
         <link>https://padlet.com/ThompsonDeanAvista/About/wish/160382551</link>
         <description><![CDATA[]]></description>
         <enclosure url="http://observer.com/2013/12/its-all-power-and-light-fixture-family-unloads-park-ave-condo-for-16-5-m/" />
         <pubDate>2017-03-15 21:25:03 UTC</pubDate>
         <guid>https://padlet.com/ThompsonDeanAvista/About/wish/160382551</guid>
      </item>
      <item>
         <title></title>
         <author>ThompsonDeanAvista</author>
         <link>https://padlet.com/ThompsonDeanAvista/About/wish/160382916</link>
         <description><![CDATA[]]></description>
         <enclosure url="http://www.bizjournals.com/southflorida/news/2016/09/30/private-equity-firm-boss-buys-new-beachfront-condo.html" />
         <pubDate>2017-03-15 21:27:17 UTC</pubDate>
         <guid>https://padlet.com/ThompsonDeanAvista/About/wish/160382916</guid>
      </item>
      <item>
         <title>Acino Announces Acquisition of Litha Healthcare</title>
         <author>ThompsonDeanAvista</author>
         <link>https://padlet.com/ThompsonDeanAvista/About/wish/175634685</link>
         <description><![CDATA[<div>The cofounder and CEO of New York-based Avista Capital Partners, Thompson Dean leverages his extensive experience as an investor in multiple business sectors to benefit Avista. Under Thompson Dean’s stewardship, Avista aims to achieve long-term returns through its hands-on approach to portfolio management. <br><br>In February of 2017, Avista announced the acquisition of South Africa’s Litha Healthcare by Acino, one of Avista’s acquired companies. The transaction, which was made alongside several Endo International subsidiaries, will bolster Acino’s efforts to enter high-potential markets in Africa and the Middle East. This will be accomplished by providing the Swedish pharmaceutical manufacturer with immediate access to an established South African presence that it can use as a platform to further its efforts throughout the continent.<br><br>The deal is anticipated to close at some point during the second quarter of 2017. Acino CEO Kalle Kand noted that the company chose Litha for its strong market positioning, established product pipeline, and existing business relationships.</div>]]></description>
         <enclosure url="" />
         <pubDate>2017-06-07 21:17:24 UTC</pubDate>
         <guid>https://padlet.com/ThompsonDeanAvista/About/wish/175634685</guid>
      </item>
      <item>
         <title>Lantheus Holdings, Inc. Announces Public Secondary Offering</title>
         <author>ThompsonDeanAvista</author>
         <link>https://padlet.com/ThompsonDeanAvista/About/wish/178484671</link>
         <description><![CDATA[<div><br>For more than a decade, Thompson Dean has led Avista Capital Partners as its chief executive officer. Thompson Dean focuses primarily on growth investments and control buyouts in the health care sector. The Avista portfolio includes <a href="http://www.businesswire.com/news/home/20170614006170/en/Lantheus-Holdings-Announces-Public-Secondary-Offering-Selling">Lantheus Holdings, Inc.,</a> which serves as the parent company of Lantheus Medical Imaging. The latter organization has emerged as a global leader in the design and manufacture of diagnostic imaging products.<br><br>Key Lantheus products are used to diagnose cardiovascular disease and include Xenon, an inhaled radiopharmaceutical imaging agent, and an echocardiography contrast agent called DEFINITY.<br><br>In June, Lantheus announced an agreement for a public secondary offering. The agreement involves the sale of 3,000,000 shares of common stock that will be offered by previously identified existing stockholders. Proceeds from the sale of these shares will benefit stockholders, not the company. The underwriters for the offering include Cantor Fitzgerald &amp; Co. and Credit Suisse Securities.<br><br>A shelf registration statement, which includes a prospectus for the offering, is currently on file with the U.S. Securities and Exchange Commission.</div>]]></description>
         <enclosure url="" />
         <pubDate>2017-07-11 14:08:40 UTC</pubDate>
         <guid>https://padlet.com/ThompsonDeanAvista/About/wish/178484671</guid>
      </item>
   </channel>
</rss>
